论文部分内容阅读
[目的]研究非小细胞肺癌(NSCLC)组织中versican蛋白的表达,探讨其与NSCLC临床病理参数及预后之间的关系。[方法]应用免疫组化方法检测80例NSCLC组织中versican蛋白表达水平,并对其与患者的临床病理特征及总生存时间(OS)关系进行分析。[结果]80例NSCLC肿瘤组织中,versican蛋白全部表达,其中强阳性表达率36.3%(29/80),弱阳性表达率63.7%(51/80)。Versican蛋白在晚期NSCLC中的强阳性表达率显著高于早期NSCLC(P=0.006)。Versican蛋白强阳性和弱阳性表达患者的中位生存时间(MST)分别为12和22个月(P=0.000)。单因素分析的结果显示,NSCLS患者的预后与肿瘤分期、淋巴结转移、分化程度、versican蛋白表达水平密切相关(P均<0.05)。Cox比例风险回归模型进行多因素分析的结果显示,肿瘤分期、淋巴结转移状态和versican蛋白的表达水平是影响NSCLC患者预后的独立因素(P均<0.05)。[结论]Versican蛋白的表达情况是NSCLC的独立预后因素,与患者的预后呈负相关。
[Objective] To investigate the expression of versican protein in non-small cell lung cancer (NSCLC) and to investigate its relationship with clinicopathological parameters and prognosis of NSCLC. [Methods] The expression of versican protein in 80 cases of NSCLC was detected by immunohistochemistry. The relationship between versican protein and the clinicopathological features and total survival time (OS) was analyzed. [Result] The versican protein was all expressed in 80 cases of NSCLC. The strong positive expression rate was 36.3% (29/80) and the weak positive expression rate was 63.7% (51/80). The strong positive expression rate of Versican protein in advanced NSCLC was significantly higher than that in early stage NSCLC (P = 0.006). The median survival time (MST) of patients with strongly and weakly positive Versican proteins was 12 and 22 months, respectively (P = 0.000). The results of univariate analysis showed that the prognosis of patients with NSCLS was closely related to tumor stage, lymph node metastasis, differentiation degree and versican protein expression (all P <0.05). Cox proportional hazards regression model for multivariate analysis showed that tumor stage, lymph node metastasis and the expression of versican protein were independent prognostic factors in NSCLC (all P <0.05). [Conclusion] The expression of Versican protein is an independent prognostic factor of NSCLC, which is negatively correlated with the prognosis of patients.